Top Stocks
Top Gainers
Latest News — DRREDDY
News
Dr Reddys Share Price Live Updates: Dr. Reddys Price and Returns Overview
News
Dr Reddys Share Price Live Updates: Market Performance of Dr. Reddys
News
Dr Reddys Share Price Live Updates: Dr. Reddys maintains a strong performance
News
Dr Reddys Share Price Live Updates: Dr. Reddys Weekly Performance
News
Dr Reddys Share Price Live Updates: Dr. Reddy's Laboratories closes lower at Rs 1342.0
News
Dr Reddys Share Price Live Updates: Dr. Reddys shows slight positive change today
News
Dr Reddys Share Price Live Updates: Dr. Reddys Stock Performance Insights
News
Dr Reddys Share Price Live Updates: Dr. Reddys records a slight increase in stock price
News
Five Stocks To Buy Today, October 27: Dr Reddy's Laboratories, Asahi India Glass, Ajanta Pharma, And More — Technical analysts recommend six stocks for today's trading, highlighting potential gains from around 4 to over 9% across sectors like pharmaceuticals and glass manufacturing.
News
Market wrap: Dr Reddys, JSW Steel, Shriram Finance, Tata Consumer top gainers and losers on Nifty and Sensex on Monday — Indian equity markets snapped a four-day losing streak as Sensex and Nifty rebounded, supported by broad-based buying. Dr Reddy’s and JSW Steel led gainers, while rising India VIX signalled continued volatility and technical concerns about downside risks.
News
Dr Reddys Share Price Live Updates: Dr. Reddys Breaks Through Resistance Level
News
Dr Reddy's Q2 Review: Brokerages Flag Margin Recovery As Key Growth Driver — Check Target Price, Potential Upside — Dr. Reddy's Laboratories delivered a sharp margin recovery and beat profit expectations despite largely in-line revenue. Brokerages highlighted operating efficiencies and a stronger product mix, while identifying semaglutide supplies and abatacept approval as key catalysts for the coming quarters.
News
Stock Picks Today: Infosys, Kotak Mahindra Bank, Dr. Reddy's, SBI Cards, And More On Brokerages' Radar — Check out the top stock calls, initiations, upgrades, downgrades, and target price revisions from leading brokerages ahead of today's trade.
News
Dr Reddy's bets on generic semaglutide, biosimilars — Dr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of generic semaglutide and the US launch of abatacept biosimilar are anticipated for future growth. The company aims to sell millions of pens for semaglutide with a focus on international markets. Furthermore, an expanding biosimilars portfolio aims to strengthen its position beyond traditional generics.
News
DRL says cap on trade margins a positive, posts 36% dip in Q2 PAT — In the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trade margin regulations that aim to improve access to vital medicines. With a commitment to boosting its core business performance, management is also dedicated to exploring growth avenues.
Want real-time updates and interactive TradingView charts? Register for a free account.
Get Live Access — Free